Rep. Bliley Cautions FDA About Internal Investigation Of "Whistleblower"
Executive Summary
The "basis and timing" for FDA's internal investigation of a scientist who raised issues about Warner-Lambert's Rezulin (troglitazone) is "puzzling," House Commerce Committee Chairman Bliley (R-Va.) wrote in a March 22 letter.
You may also be interested in...
Warner-Lambert Rezulin
FDA's Endocrine & Metabolic Drugs Advisory Committee will meet May 19 to hear FDA's presentation of data and to discuss the rationale behind the March 21 withdrawal of the type 2 diabetes therapy troglitazone from the U.S. market (1"The Pink Sheet" March 27, p. 5). The committee will meet at the Holiday Inn in Bethesda, Md. at 10 a.m
Warner-Lambert Rezulin
FDA's Endocrine & Metabolic Drugs Advisory Committee will meet May 19 to hear FDA's presentation of data and to discuss the rationale behind the March 21 withdrawal of the type 2 diabetes therapy troglitazone from the U.S. market (1"The Pink Sheet" March 27, p. 5). The committee will meet at the Holiday Inn in Bethesda, Md. at 10 a.m
Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal
The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.